Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-25-021313
Filing Date
2025-05-01
Accepted
2025-05-01 07:02:41
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14a2025.htm DEFA14A 12831
2 GRAPHIC avalotherapeuticsinc_vxn001.jpg GRAPHIC 155339
3 GRAPHIC avalotherapeuticsinc_vxn002.jpg GRAPHIC 111901
  Complete submission text file 0001628280-25-021313.txt   382229
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37590 | Film No.: 25899345
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)